GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » PB Ratio

Ascletis Pharma (HKSE:01672) PB Ratio : 0.49 (As of May. 31, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-31), Ascletis Pharma's share price is HK$1.21. Ascletis Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was HK$2.46. Hence, Ascletis Pharma's PB Ratio of today is 0.49.

Good Sign:

Ascletis Pharma Inc stock PB Ratio (=0.51) is close to 10-year low of 0.49

The historical rank and industry rank for Ascletis Pharma's PB Ratio or its related term are showing as below:

HKSE:01672' s PB Ratio Range Over the Past 10 Years
Min: 0.49   Med: 0.97   Max: 17.18
Current: 0.51

During the past 8 years, Ascletis Pharma's highest PB Ratio was 17.18. The lowest was 0.49. And the median was 0.97.

HKSE:01672's PB Ratio is ranked better than
93.52% of 1311 companies
in the Biotechnology industry
Industry Median: 2.52 vs HKSE:01672: 0.51

During the past 12 months, Ascletis Pharma's average Book Value Per Share Growth Rate was -5.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -8.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -7.00% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Ascletis Pharma was 130.80% per year. The lowest was -8.50% per year. And the median was -4.20% per year.

Back to Basics: PB Ratio


Ascletis Pharma PB Ratio Historical Data

The historical data trend for Ascletis Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma PB Ratio Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 0.89 0.90 1.08 1.82 0.59

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.30 1.82 0.72 0.59

Competitive Comparison of Ascletis Pharma's PB Ratio

For the Biotechnology subindustry, Ascletis Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascletis Pharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's PB Ratio falls into.



Ascletis Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Ascletis Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.21/2.457
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Ascletis Pharma  (HKSE:01672) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Ascletis Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma (HKSE:01672) Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.
Executives
Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines